Jun 2, 2021
NLS Pharmaceutics to Present at the LD Micro Virtual Invitational Conference on June 10, 2021
READ PRESS RELEASE
May 28, 2021
NLS Pharmaceutics to Present at The MicroCap Rodeo 2021 Summer Solstice: Best Ideas from the Buyside Conference on June 1
READ PRESS RELEASE
May 18, 2021
NLS Pharmaceutics Announces New Study Data Confirming Mazindol’s Unique Orexin Pathway Activation for Treating Narcolepsy
READ PRESS RELEASE
May 5, 2021
NLS Pharmaceutics Announces Patent Issuance in Europe for its Mazindol Controlled-Release Formulation (Mazindol CR)
READ PRESS RELEASE
Mar 29, 2021
NLS Pharmaceutics Appoints Silvia Panigone, Ph.D. As Chief Operating Officer
READ PRESS RELEASE
Mar 29, 2021
NLS Pharmaceutics Announces Issuance of Canadian Patent Covering its Novel Formulation of Controlled-Release Mazindol (Mazindol CR)
READ PRESS RELEASE
Mar 13, 2021
NLS Pharmaceutics Obtains License to Full Regulatory Data Package and Proprietary Know-How for Sanorex® (Mazindol)
READ PRESS RELEASE
Feb 25, 2021
NLS Pharmaceutics to Participate in Upcoming Investor Conferences
READ PRESS RELEASE
Feb 2, 2021
NLS Pharmaceutics Ltd. Announces Closing of $20.0 Million Initial Public Offering
READ PRESS RELEASE
Jan 28, 2021
NLS Pharmaceutics Ltd. Announces Pricing of $20.0 Million Initial Public Offering
READ PRESS RELEASE
Jan 21, 2021
NLS Pharmaceutics Ltd. Announces Notice of Allowance of a new Technology Patent Covering Attention Deficit Hyperactivity Disorder & Narcolepsy
READ PRESS RELEASE
Recent Comments